Evidence map›Paper›PMID 31198269›Full record

ArticleNigerian medical journal : journal of the Nigeria Medical Association

Prevalence of Rifampicin-Resistant Tuberculosis among Patients Previously Treated for Pulmonary Tuberculosis in North-Western, Nigeria.

Abayomi Fadeyi, Olufemi O Desalu, Chidi Ugwuoke, Oji A Opanwa, Charles Nwabuisi, Alakija K Salami

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nigerian medical journal : journal of the Nigeria Medical Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Abayomi FadeyiDepartment of Medical Microbiology and Parasitology, University of Ilorin, Ilorin, Kwara State, Nigeria.
Olufemi O DesaluDepartment of Medicine, University of Ilorin Teaching Hospital, Ilorin, Kwara State, Nigeria.
Chidi UgwuokeDepartment of Medical Microbiology and Parasitology, University of Ilorin, Ilorin, Kwara State, Nigeria.
Oji A OpanwaDepartment of Chest, Infectious Disease Hospital, Kano, Kano State, Nigeria.
Charles NwabuisiDepartment of Medical Microbiology and Parasitology, University of Ilorin, Ilorin, Kwara State, Nigeria.
Alakija K SalamiDepartment of Medicine, University of Ilorin Teaching Hospital, Ilorin, Kwara State, Nigeria.
University of Ilorin · NGUniversity of Ilorin Teaching Hospital · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDrug-resistant tuberculosis (TB) is a significant public health problem. Greater than 90% of rifampicin (RIF)-resistant isolates were also isoniazid resistant, and hence, rifampicin resistance (RR) is frequently used as a surrogate for multidrug-resistant TB.

settingThis study was conducted at Infectious Disease Hospital Kano in North-Western Nigeria.

objectivesThe aim of this study was to determine the prevalence of RR among patients previously treated for pulmonary TB (PTB). MATERIALS AND

methodsA total of 120 patients previously treated for PTB with current clinical features of PTB were recruited into this study. Relevant clinical information were obtained using a questionnaire. The sputum was collected and analyzed by the Gene Xpert MTB/RIF

resultsThe mean (±standard deviation) age of the participants was 35.9 ± 14.3 years and they comprised 73 (60.8%) males and 47 (39.2%) females. HIV-seropositive rate was 11.7% among the participants. Of the 120 participants, PTB was detected in 35 (29.2%) of the participants by Gene Xpert MTB/RIF and 29 of them were cases of relapse. Five patients (4.2%) had RR tuberculosis and 80% of them were below the age of 45 years.

conclusionThe prevalence of RR is not high among previously treated PTB patients in this study when compared with other previous studies. This finding is a window for evaluating the efficacy of current interventions in the region and evidence for the consolidation of existing control policies.

Indexed as

Drug resistancemultidrug-resistant tuberculosisrifampicintuberculosis

Identifiers

PMID31198269
PMCPMC6555224
OpenAlexW2946910828

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.